Avidian Wealth Enterprises’s TherapeuticsMD TXMD Stock Holding History

Avidian Wealth Enterprises’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-217	Closed	-$4K	–	501
2022 Q1	$4K	Hold	217	–	–	﹤0.01%	487
2021 Q4	$4K	Sell	217 -2	-0.9%	-$60	﹤0.01%	535
2021 Q3	$8K	Buy	219 +2	+0.9%	+$89	﹤0.01%	387
2021 Q2	$13K	Hold	217	–	–	﹤0.01%	393
2021 Q1	$15K	Hold	217	–	–	﹤0.01%	367
2020 Q4	$13K	Hold	217	–	–	﹤0.01%	327
2020 Q3	$17K	Hold	217	–	–	﹤0.01%	280
2020 Q2	$14K	Hold	217	–	–	﹤0.01%	249
2020 Q1	$12K	Sell	217 -100	-32%	-$9.91K	﹤0.01%	209
2019 Q4	$38K	Hold	317	–	–	0.01%	226
2019 Q3	$58K	Hold	317	–	–	0.01%	188
2019 Q2	$41K	Hold	317	–	–	0.01%	145
2019 Q1	$77K	Buy	317 +40	+14%	+$10.6K	0.02%	131
2018 Q4	$53K	Hold	277	–	–	0.02%	91
2018 Q3	$91K	Hold	277	–	–	0.03%	102
2018 Q2	$87K	Hold	277	–	–	0.03%	99
2018 Q1	$68K	Hold	277	–	–	0.02%	97
2017 Q4	$84	Hold	277	–	–	0.02%	104
2017 Q3	$73K	Hold	277	–	–	0.03%	89
2017 Q2	$73K	Buy	+277	New	+$69.4K	0.03%	87

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Avidian Wealth Enterprises's TXMD Position: Q2 2022 in Review

Avidian Wealth Enterprises sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 217 shares — an estimated $4K sold.

Avidian Wealth Enterprises first reported a position in TXMD in Q2 2017 and held it in 20 quarters. The position peaked at $91K in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Avidian Wealth Enterprises reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Avidian Wealth Enterprises sold 217 TherapeuticsMD shares in Q2 2022, an estimated $4K.
Avidian Wealth Enterprises first reported a position in TherapeuticsMD in Q2 2017 and held it in 20 quarters.
Avidian Wealth Enterprises's TherapeuticsMD position peaked at $91K in Q3 2018.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Avidian Wealth Enterprises's 13F filing for Q2 2022, filed 29 Jul 2022.